Biomind Labs Announces Upgrade to the OTCQB® Venture Market in the United States
Ryan Allway February 17th, 2022 Psychedelics, Top News TORONTO, February 17, 2022–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company“) (NEO: BMND) (OTC: CRSWF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) for the treatment of mental health disorders and... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )